1. A light emitting device comprising:
a substrate having a mounting surface; and
one hundred or more light emitting elements placed on the mounting surface of the substrate, the light emitting elements each having a light emitting area of 2,500\u03c0 \u03bcm2 or less,
at least one of the light emitting elements being in shape of a bar,
the at least one light emitting element in shape of a bar having a cylindrical light emitting surface that concentrically surrounds a bar-like core,
no pn junctions, which are perpendicular to an axis direction of the bar, existing in the middle of the bar, and
an area of the mounting surface of the substrate being equal to or larger than four times as large as a sum total of the light emitting areas of the light emitting elements.
2. The light emitting device as claimed in claim 1, wherein
the bar-like core of the at least one light emitting element is an n-type semiconductor core, and
the at least one light emitting element has a cylindrical p-type semiconductor layer covering an outer peripheral surface of the n-type semiconductor core.
3. The light emitting device as claimed in claim 1, wherein the light emitting area of each of the light emitting elements is not larger than 625\u03c0 \u03bcm2.
4. The light emitting device as claimed in claim 3, wherein
difference between a center temperature of the light emitting surface and an end part temperature of the light emitting surface is around zero during light emitting operations of the light emitting elements.
5. The light emitting device as claimed in claim 1, wherein
the light emitting elements are placed on the mounting surface of the substrate while being dispersed uniformly in general.
6. An illuminating device comprising the light emitting device as claimed in claim 1.
7. A backlight comprising the light emitting device as claimed in claim 1.
8. A light emitting device comprising:
a substrate having a mounting surface; and
one hundred or more light emitting elements placed on the mounting surface of the substrate, the light emitting elements each having a light emitting area of 2,500\u03c0 \u03bcm 2 or less,
an area of the mounting surface of the substrate being equal to or larger than four times as large as a sum total of the light emitting areas of the light emitting elements.
9. The light emitting device as claimed in claim 8, wherein the light emitting area of each of the light emitting elements is not larger than 625\u03c0 \u03bcm 2.
10. The light emitting device as claimed in claim 9, wherein
difference between a center temperature of the light emitting surface and an end part temperature of the light emitting surface is around zero during light emitting operations of the light emitting elements are emitting light.
11. The light emitting device as claimed in claim 8, wherein the light emitting elements are dispersed uniformly in general on the mounting surface of the substrate.
12. The light emitting device as claimed in claim 8, wherein each of the light emitting elements has a flat light emitting surface or a cylindrical light emitting surface.
13. An illuminating device comprising the light emitting device as claimed in claim 8.
14. A backlight comprising the light emitting device as claimed in claim 8.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound of formula (I)
or a pharmaceutically acceptable salt thereof; wherein
X is a linker group selected from \u2014CR4\u2550CR5\u2014, \u2014CR4\u2550CR5CR6R7\u2014, \u2014CR6R7CR5\u2550CR4\u2014, \u2014C\u2261C\u2014, \u2014C\u2261CCR6R7\u2014, \u2014NR4CR6R7\u2014, \u2014OCR6R7\u2014, \u2014SCR6R7\u2014, \u2014S(O)CR6R7\u2014, \u2014S(O)2CR6R7\u2014, \u2014C(O)NR4CR6R7\u2014, \u2014NR4C(O)CR6R7\u2014, \u2014NR4C(O)NR5CR6R7\u2014, \u2014NR4S(O)2CR6R7\u2014, \u2014S(O)2NR4CR6R7\u2014, \u2014C(O)NR4\u2014, \u2014NR4C(O)\u2014, \u2014NR4C(O)NR5\u2014, \u2014S(O)2NR4\u2014 and \u2014NR4S(O)2\u2014;
1Y and Y2 are independently N or CR8 provided that one of 1Y and Y2 is N and the other is CR8;
R1 is a group selected from C1-6alkyl, C2-6alkenyl, C2-6alkynyl, carbocyclyl, carbocyclylC1-6alkyl, heterocyclyl and heterocyclylC1-6alkyl, which group is optionally substituted by one or more substituent group selected from halo, cyano, nitro, R9, \u2014OR9, \u2014SR9, \u2014SO2R9, \u2014COR9, \u2014CO2R9, \u2014CONR9R10, \u2014NR9R10, \u2014NR9COR10, \u2014NR9CO2R10, \u2014NR9CONR10R15, \u2014NR9COCONR10R15 and \u2014NR9SO2R10;
R2 is a group selected from C1 alkyl, carbocyclyl and heterocyclyl which group is optionally substituted by one or more substituent group independently selected from halo, cyano, nitro, \u2014R11, \u2014OR11, \u2014SR11, \u2014SOR11, \u2014SO2R11, \u2014COR11, \u2014CO2R11, \u2014CONR11R12, \u2014NR11R12, and \u2014NR11COCONR12R16;
R3 is selected from halo, cyano, nitro, \u2014R13, \u2014OR13, \u2014SR13, \u2014SOR13, \u2014SO2R13, \u2014COR13, \u2014CO2R13, \u2014CONR13R14, \u2014NR13R14, \u2014NR13COR14, \u2014NR13CO2R14 and \u2014NR13SO2R14;
R4 and R5 are independently hydrogen or C1-6alkyl;
or R1 and R4 together with the atom or atoms to which they are attached form a 4- to 10-membered carbocyclic or heterocyclic ring wherein 1, 2 or 3 ring carbon atoms is optionally replaced with N, O or S and which ring is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, oxo, C1-6alkyl, C1-6alkoxy, haloC1-6alkyl, haloC1-6alkoxy, hydroxyC1-6alkyl, hydroxyC1-6allcoxy, C1-6alkoxyC1-6alkyl, C1-6alkoxyC1-6alkoxy, amino, C1-6alkylamino, bis(C1-6alkyl)amino, aminoC1-6alkyl, (C1-6alkyl)aminoC1-6alkyl, bis(C1-6alkyl)aminoC1-6alkyl, cyanoC1-6alkyl, C1-6alkylsulfonyl, C1-6alkylsulfonylamino, C1-6alkylsulfonyl(C1-6alkyl)amino, sulfamoyl, C1-6alkylsulfamoyl, bis(C1-6alkyl)sulfamoyl, C1-6alkanoylamino, C1-6alkanoyl(C1-6alkyl)amino, carbamoyl, C1-6alkylcarbamoyl and bis(C1-6alkyl)carbamoyl;
R6 and R7 are independently selected from hydrogen, halo, cyano, nitro and C1-6alkyl;
R8 is selected from hydrogen, halo, cyano and C1-6alkyl;
R9 and R10 are independently hydrogen or a group selected from C1-6alkyl, carbocyclyl, carbocyclylC1-6alkyl, heterocyclyl and heterocyclylC1-6alkyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C1-6C1-6alkoxy, haloC1-6alkyl, haloC1-6alkoxy, hydroxyC1-6alkyl, hydroxyC1-6alkoxy, alkoxyC1-6alkyl, C1-6alkoxyC1-6alkoxy, amino, C1-6alkylamino, bis(C1-6alkyl)amino, aminoC1-6alkyl, (C1-6alkyl)aminoC1-6alkyl, bis(C1-6alkyl)aminoC1-6alkyl, cyanoC1-6alkyl, C1-6alkylsulfonyl, C1-6alkylsulfonylamino, C1-6alkylsulfonyl(C1-6alkyl)amino, sulfamoyl, C1-6alkylsulfamoyl, bis(C1-6alkyl)sulfamoyl, C1-6alkanoylamino, C1-6alkanoyl(C1-6alkyl)amino, carbamoyl, C1-6alkylcarbamoyl and bis(C1-6alkyl)carbamoyl;
R11 and R12 are independently hydrogen or a group selected from C1-6alkyl, carbocyclyl, carbocyclylC1-6alkyl, heterocyclyl and heterocyclylC1-6alkyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C1-6alkyl, C1-6alkoxy, haloC1-6alkyl, haloC1-6alkoxy, hydroxyC1-6alkyl, hydroxyC1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkoxyC1-6alkoxy, amino, C1-6alkylamino, bis(C1-6alkyl)amino, aminoC1-6alkyl, (C1-6alkyl)aminoC1-6alkyl, bis(C1-6alkyl)aminoC1-6alkyl, cyanoC1-6alkyl, C1-6alkylsulfonyl, C1-6alkanoylamino, C1-6alkanoyl(C1-6alkyl)amino, carbamoyl, C1-6alkylcarbamoyl and bis(C1-6alkyl)carbamoyl;
R13, R14, R15 and R16 are independently hydrogen or a group selected from C1-6alkyl, carbocyclyl, carbocyclylC1-6alkyl, heterocyclyl and heterocyclylC1-6alkyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C1-6alkyl, C1-6alkoxy, haloC1-6alkyl, haloC1-6alkoxy, hydroxyC1-6alkyl, hydroxyC1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkoxyC1-6alkoxy, amino, C1-6alkylamino, bis(C1-6alkyl)amino, aminoC1-6alkyl, (C1-6alkyl)aminoC1-6alkyl, bis(C1-6alkyl)aminoC1-6alkyl, cyanoC1-6alkyl, C1-6alkylsulfonyl, C1-6alkylsulfonylamino, C1-6alkylsulfonyl(C1-6alkyl)amino, sulfamoyl, C1-6alkylsulfamoyl, bis(C1-6alkyl)sulfamoyl, C1-6alkanoylamino, C1-6alkanoyl(C1-6alkyl)amino, carbamoyl, C1-6alkylcarbamoyl and bis(C1-6alkyl)carbamoyl.
2. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1 wherein 1Y is CH and Y2 is N.
3. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1 wherein X is \u2014S(O)2CR6R7\u2014 or \u2014C(O)NHR4\u2014.
4. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 3 wherein X is \u2014S(O)2CH2\u2014, \u2014S(O)2CH(CH3)\u2014, \u2014S(O)2C(CH3)2\u2014 or \u2014C(O)NH\u2014.
5. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1 wherein R1 is a group selected from methyl, ethyl, isopropyl, sec-butyl, isobutyl, phenyl, 2-methoxyphenyl, 3-methoxyphenyl, 3-fluoro-4-methoxyphenyl, 4-methoxy-3-trifluoromethylphenyl, 2-methoxypyridin-5-yl, 2-methoxypyridin-4-yl, 2-methoxypyridin-4-yl, 2-acetamidopyridin-5-yl, 2-acetamidopyridin-4-yl and 4-(anilinocarbonyl)aminophenyl.
6. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 5 wherein \u2014XR1 is a group selected from \u2014CH2SO2\u2014R1 and \u2014C(CH3)2SO2\u2014R1 wherein R1 is methyl, ethyl, isopropyl, sec-butyl, isobutyl or phenyl; or \u2014XR1 is \u2014NHCO\u2014R1 wherein R1 is 2-methoxyphenyl, 3-methoxyphenyl, 3-fluoro-4-methoxyphenyl, 4-methoxy-3-trifluoromethylphenyl, 2-methoxypyridin-5-yl, 2-methoxypyridin-4-yl, 2-methoxypyridin-4-yl, 2-acetamidopyridin-5-yl, 2-acetamidopyridin-4-yl or 4-(anilinocarbonyl)aminophenyl.
7. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1 wherein R2 is selected from morpholinyl, piperidinyl, phenyl, naphthyl, pyrrolyl, imidazolyl, pyrazolyl, furanyl, thienyl, pyridinyl, pyrimidinyl, pyridazinyl, azaindolyl, indolyl, quinolinyl, benzimidazolyl, benzofuranyl, dibenzofuranyl, benzothienyl which group is optionally substituted by one or more substituent group independently selected from halo, methyl, methoxy, hydroxymethyl, cyanomethyl, phenoxy, pyrrolidinyl, \u2014CONH2, \u2014CONHCH3 and \u2014CON(CH3)2.
8. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1 wherein R2 is (pyrazol-3yl)amino, hydroxypiperidinyl, indol-4-yl, indol-5-yl, indol-6-yl, azaindolyl, benzimidazol-5-yl, 3-(pyrazol-4-yl)phenyl, 4-(pyrazol-4-yl)phenyl, 2-aminocarbonylindol-5-yl, 3-aminocarbonylindol-5-yl, 2-aminocarbonylindol-6-yl, 3-aminocarbonylindol-6-yl, morpholinyl, 2-(pyrazol-4-yl)thiazol-5yl or methylmorpholinyl.
9. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1 selected from any one of
N-4,6-Bis(3S)-3-methylmorpholin-4-ylpyrimidin-2-yl-4-methoxy-benzamide,
N-2,6-Bis(3S)-3-methylmorpholin-4-ylpyrimidin-4-yl-4-methoxy-3-(trifluoromethyl)benzamide,
N-2,6-Bis(3S)-3-methylmorpholin-4-ylpyrimidin-4-yl-3-methoxy-benzamide,
N-4,6-Bis(3S)-3-methylmorpholin-4-ylpyrimidin-2-yl-4-methoxy-3-(trifluoromethyl)benzamide,
N-4,6-Bis(3S)-3-methylmorpholin-4-ylpyrimidin-2-yl-3-methoxy-benzamide,
N-4,6-Bis(3S)-3-methylmorpholin-4-ylpyrimidin-2-yl-6-methoxy-pyridine-3-carboxamide,
N-2,6-Bis(3S)-3-methylmorpholin-4-ylpyrimidin-4-yl-2-methoxy-pyridine-4-carboxamide,
6-Acetamido-N-2,6-bis(3S)-3-methylmorpholin-4-ylpyrimidin-4-ylpyridine-3-carboxamide,
N-2,6-Bis(3S)-3-methylmorpholin-4-ylpyrimidin-4-yl-2-methoxy-benzamide,
2-Acetamido-N-2,6-bis(3S)-3-methylmorpholin-4-ylpyrimidin-4-ylpyridine-4-carboxamide,
N-2,6-Bis(3S)-3-methylmorpholin-4-ylpyrimidin-4-yl-3-fluoro-4-methoxy-benzamide,
N-4,6-Bis(3S)-3-methylmorpholin-4-ylpyrimidin-2-yl-2-methoxy-pyridine-4-carboxamide,
6-Acetamido-N-4,6-bis(3S)-3-methylmorpholin-4-ylpyrimidin-2-ylpyridine-3-carboxamide,
N-4,6-Bis(3S)-3-methylmorpholin-4-ylpyrimidin-2-yl-2-methoxy-benzamide,
2-Acetamido-N-4,6-bis(3S)-3-methylmorpholin-4-ylpyrimidin-2-ylpyridine-4-carboxamide,
N-4,6-Bis(3S)-3-methylmorpholin-4-ylpyrimidin-2-yl-3-fluoro-4-methoxy-benzamide,
N-2,6-Bis(3S)-3-methylmorpholin-4-ylpyrimidin-4-yl-4-(phenylcarbamoylamino)benzamide,
N-4,6-Bis(3S)-3-methylmorpholin-4-ylpyrimidin-2-yl-4-(phenylcarbamoylamino)benzamide,
N-2,6-Bis(3S)-3-methylmorpholin-4-ylpyrimidin-4-yl-4-methoxy-benzamide,
2-(2R,6S)-2,6-Dimethylmorpholin-4-yl-4-(3S)-3-methylmorpholin-4-yl-6-(methylsulfonylmethyl)pyrimidine,
1-4-(3S)-3-Methylmorpholin-4-yl-6-(methylsulfonylmethyl)pyrimidin-2-ylpiperidin-3-ol,
4-(3S)-3-methylmorpholin-4-yl-6-(methylsulfonylmethyl)-2-morpholin-4-yl-pyrimidine,
3-4-(3S)-3-Methylmorpholin-4-yl-6-(methylsulfonylmethyl)pyrimidin-2-yl-5,7-diazabicyclo4.3.0nona-1,3,5,8-tetraene,
5-4-(3S)-3-Methylmorpholin-4-yl-6-(methylsulfonylmethyl)pyrimidin-2-yl-1H-indole,
5-4-(3R)-3-methylmorpholin-4-yl-6-(methylsulfonylmethyl)pyrimidin-2-yl-1H-indole,
5-4-(Butan-2-ylsulfonylmethyl)-6-(3S)-3-methylmorpholin-4-ylpyrimidin-2-yl-1H-indole,
5-4-(butan-2-ylsulfinylmethyl)-6-(3R)-3-methylmorpholin-4-ylpyrimidin-2-yl-1H-indole,
5-4-(3R)-3-methylmorpholin-4-yl-6-(propan-2-ylsulfonylmethyl)pyrimidin-2-yl-1H-indole,
5-4-(ethylsulfonylmethyl)-6-(3R)-3-methylmorpholin-4-ylpyrimidin-2-yl-1H-indole,
4-(3S)-3-Methylmorpholin-4-yl-6-(methylsulfonylmethyl)-N-(1H-pyrazol-3-yl)pyrimidin-2-amine,
4-(3S)-3-Methylmorpholin-4-yl-6-(methylsulfonylmethyl)-2-4-(1H-pyrazol-4-yl)phenylpyrimidine,
4-(3S)-3-Methylmorpholin-4-yl-6-(methylsulfonylmethyl)-2-3-(1H-pyrazol-4-yl)phenylpyrimidine,
5-4-(3S)-3-Methylmorpholin-4-yl-6-(methylsulfonylmethyl)pyrimidin-2-yl-1H-indole-3-carboxamide,
4-(3S)-3-Methylmorpholin-4-yl-6-(methylsulfonylmethyl)-2-2-(1H-pyrazol-4-yl)-1,3-thiazol-5-ylpyrimidine,
6-4-(3S)-3-Methylmorpholin-4-yl-6-(methylsulfonylmethyl)pyrimidin-2-yl-1H-indole,
6-4-(3S)-3-Methylmorpholin-4-yl-6-(methylsulfonylmethyl)pyrimidin-2-yl-1H-indole-3-carboxamide,
5-4-(3S)-3-Methylmorpholin-4-yl-6-(methylsulfonylmethyl)pyrimidin-2-yl-1H-indole-2-carboxamide,
6-4-(3S)-3-Methylmorpholin-4-yl-6-(methylsulfonylmethyl)pyrimidin-2-yl-1H-indole-2-carboxamide,
5-4-(3S)-3-Methylmorpholin-4-yl-6-(2-methylsulfonylpropan-2-yl)pyrimidin-2-yl-1H-benzoimidazole,
3-4-(3S)-3-Methylmorpholin-4-yl-6-(2-methylsulfonylpropan-2-yl)pyrimidin-2-yl-5,7-diazabicyclo4.3.0nona-1,3,5,8-tetraene,
5-4-(3S)-3-methylmorpholin-4-yl-6-(2-methylsulfonylpropan-2-yl)pyrimidin-2-yl-1H-indole,
4-4-(3S)-3-methylmorpholin-4-yl-6-(2-methylsulfonylpropan-2-yl)pyrimidin-2-yl-1H-indole,
6-4-(3S)-3-methylmorpholin-4-yl-6-(2-methylsulfonylpropan-2-yl)pyrimidin-2-yl-1H-indole,
4-4-(Benzenesulfonylmethyl)-6-(3S)-3-methylmorpholin-4-ylpyrimidin-2-yl-1H-indole,
5-4-(benzenesulfonylmethyl)-6-(3S)-3-methylmorpholin-4-ylpyrimidin-2-yl-1H-indole,
3-4-(benzenesulfonylmethyl)-6-(3S)-3-methylmorpholin-4-ylpyrimidin-2-yl-5,7-diazabicyclo4.3.0nona-1,3,5,8-tetraene,
6-4-(benzenesulfonylmethyl)-6-(3S)-3-methylmorpholin-4-ylpyrimidin-2-yl-1H-indole, or
5-4-(benzenesulfonylmethyl)-6-(3S)-3-methylmorpholin-4-ylpyrimidin-2-yl-1H-benzoimidazole, or a pharmaceutically acceptable salt thereof.
10-13. (canceled)
14. A method for producing an anti-proliferative effect in a warm-blooded animal in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined in claim 1.
15. A method for treating cancer, inflammatory diseases, obstructive airways diseases, immune diseases or cardiovascular diseases in a warm blooded animal that is in need of such treatment which comprises administering an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined in claim 1.
16. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier.
17. (canceled)
18. A method for treating cancer, inflammatory diseases, obstructive airways diseases, immune diseases or cardiovascular diseases in a warm blooded animal that is in need of such treatment which comprises administering an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined in claim 9.
19. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 9, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier.